Newsfile Corp
01 Jun 2026, 07:15 UTC · 1h ago
Source · https://www.newsfilecorp.com/release/299499/Defence-Therapeutics-Appoints-Antibody-Drug-Conjugates-Pioneer-Dr.-John-Lambert-to-Its-Board-of-Directors
Read source
Search tags
Story key points
2 claims · impact-rated
Defence Therapeutics has appointed ADC pioneer Dr. John Lambert, a former ImmunoGen executive linked to KADCYLA and ELAHERE, to its Board of Directors. — Adding a globally recognized expert with a track record of successful FDA-approved ADC drugs provides significant strategic validation and technical credibility to the company's platform.
+0.60The company granted Dr. Lambert 150,000 incentive stock options exercisable at 58 cents per share. — The exercise price provides a nominal baseline for perceived internal valuation, though the volume is relatively small.
+0.20Ticker attribution
Model heads
The company appointed a world-renowned expert in antibody-drug conjugates to its Board of Directors, validating its technology platform.
Continue reading
6 related stories
Mentioned only in the historical context of a product approval from 2013.
Mentioned only in the historical context of a product discovery.
Mentioned only as the acquirer of ImmunoGen in 2024 with no current impact.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
1d ago
